Boston Scientific Corp. has lit up the health care industry news pages arguably more than any other blue chip global medtech over the past 15 years – hugely acquisitive in 2004-2005, entering neuomodulation, working at the cutting edge of cardiovascular implant technology, stretching and stretching again to bring in Guidant in 2006, watching the share price dip below $5 in mid-2012, making ex-J&J's Mike Mahoney CEO in 2012, watching the share price recover, buying Vessix Vascular and Bard EP, and since spring 2018, bringing seven more innovative companies into the group.
Alongside organic R&D, M&A is clearly very important to Boston's growth, a fact that Ian Meredith, MD, PhD, appreciated long...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?